Show/Hide Menu
Hide/Show Apps
Logout
Türkçe
Türkçe
Search
Search
Login
Login
OpenMETU
OpenMETU
About
About
Open Science Policy
Open Science Policy
Open Access Guideline
Open Access Guideline
Postgraduate Thesis Guideline
Postgraduate Thesis Guideline
Communities & Collections
Communities & Collections
Help
Help
Frequently Asked Questions
Frequently Asked Questions
Guides
Guides
Thesis submission
Thesis submission
MS without thesis term project submission
MS without thesis term project submission
Publication submission with DOI
Publication submission with DOI
Publication submission
Publication submission
Supporting Information
Supporting Information
General Information
General Information
Copyright, Embargo and License
Copyright, Embargo and License
Contact us
Contact us
Drug Repurposing Approach to Identify Candidate Drug Molecules for Hepatocellular Carcinoma
Download
ijms-25-09392-v2.pdf
Date
2024-09-01
Author
Baser, Tugce
Rifaioğlu, Ahmet Süreyya
Atalay, Mehmet Volkan
Atalay, Rengül
Metadata
Show full item record
This work is licensed under a
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
.
Item Usage Stats
24
views
4
downloads
Cite This
Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer, with a high mortality rate due to the limited therapeutic options. Systemic drug treatments improve the patient’s life expectancy by only a few months. Furthermore, the development of novel small molecule chemotherapeutics is time-consuming and costly. Drug repurposing has been a successful strategy for identifying and utilizing new therapeutic options for diseases with limited treatment options. This study aims to identify candidate drug molecules for HCC treatment through repurposing existing compounds, leveraging the machine learning tool MDeePred. The Open Targets Platform, UniProt, ChEMBL, and Expasy databases were used to create a dataset for drug target interaction (DTI) predictions by MDeePred. Enrichment analyses of DTIs were conducted, leading to the selection of 6 out of 380 DTIs identified by MDeePred for further analyses. The physicochemical properties, lipophilicity, water solubility, drug-likeness, and medicinal chemistry properties of the candidate compounds and approved drugs for advanced stage HCC (lenvatinib, regorafenib, and sorafenib) were analyzed in detail. Drug candidates exhibited drug-like properties and demonstrated significant target docking properties. Our findings indicated the binding efficacy of the selected drug compounds to their designated targets associated with HCC. In conclusion, we identified small molecules that can be further exploited experimentally in HCC therapeutics. Our study also demonstrated the use of the MDeePred deep learning tool in in silico drug repurposing efforts for cancer therapeutics.
Subject Keywords
drug candidate
,
drug repurposing
,
hepatocellular carcinoma
,
machine learning
,
MDeePred
URI
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85204120793&origin=inward
https://hdl.handle.net/11511/111118
Journal
International Journal of Molecular Sciences
DOI
https://doi.org/10.3390/ijms25179392
Collections
Department of Computer Engineering, Article
Citation Formats
IEEE
ACM
APA
CHICAGO
MLA
BibTeX
T. Baser, A. S. Rifaioğlu, M. V. Atalay, and R. Atalay, “Drug Repurposing Approach to Identify Candidate Drug Molecules for Hepatocellular Carcinoma,”
International Journal of Molecular Sciences
, vol. 25, no. 17, pp. 0–0, 2024, Accessed: 00, 2024. [Online]. Available: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85204120793&origin=inward.